Bi-functional shRNA targeting Stathmin 1 and uses thereof
The present invention includes bifunctional shRNAs capable of reducing an expression of a Stathmin 1 gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Stathmin 1 gene, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Stathmin 1.
1. A method of suppressing a tumor cell growth in a human subject comprising the steps of:
identifying the human subject in need for suppression of the tumor cell growth; and
administering an expression vector in a therapeutic agent carrier complex to the human subject in an amount sufficient to suppress the tumor cell growth, wherein the expression vector expresses one or more shRNAs capable of inhibiting an expression of a target gene that is Stathmin 1 in the one or more target cells via RNA interference;
wherein the one or more shRNAs comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the target gene;
wherein the inhibition results in an apoptosis, an arrested proliferation, or a reduced invasiveness of the tumor cells.
2. The method of claim 1 , wherein the therapeutic agent carrier comprises a bilamellar invaginated vesicle (BIV).
3. The method of claim 1 , wherein the therapeutic agent carrier comprises one or more receptor targeting moieties that are small molecule bivalent beta-turn mimics.
4. The method of claim 1 , wherein administering is selected from the group consisting of subcutaneous, intravenous, intraperitoneal, intramuscular, and intravenous injection.
5. The method of claim 1 , wherein administering comprises intratumoral injection.
6. The method of claim 1 , wherein administering comprises injecting with a DNA:lipoplex.
7. The method of claim 1 , wherein the bifunctional RNA molecule targets at least one of the 5′-UTR or the 3′UTR of Stathmin-1.
8. The method of claim 1 , wherein the bifunctional shRNA comprises a RNA sequence defined by DNA SEQ ID NO: 3.
9. The method of claim 1 , wherein the bifunctional shRNA comprises a RNA sequence defined by DNA SEQ ID NO: 4.
10. The method of claim 1 , wherein the bifunctional shRNA comprises a RNA sequence defined by DNA SEQ ID NO: 5.
11. The method of claim 1 , wherein at least one target site sequence is within a Stathmin 1 gene cDNA sequence.
12. The method of claim 1 , wherein at least one target site sequence is defined by SEQ ID NO: 1 or SEQ ID NO: 2.
13. The method of claim 1 , wherein the therapeutic agent carrier is a compacted DNA nanoparticle.
14. The method of claim 13 , wherein the DNA nanoparticle is compacted with one or more polycations.
15. The method of claim 14 , wherein the one or more polycations is a 10 kDA polyethylene glycol (PEG)-substituted cysteine-lysine 3-mer peptide (CK30PEG10k).
16. The method of claim 13 , wherein the compacted DNA nanoparticles are further encapsulated in a liposome.
17. The method of claim 1 , wherein the therapeutic agent carrier is a liposome.
18. The method of claim 17 , wherein the liposome is a reversibly masked liposome.
19. A method of suppressing a tumor cell growth in a subject comprising the steps of:
identifying the human subject in need for suppression of the tumor cell growth; and
administering a composition comprising an expression vector that expresses one or more shRNAs capable of inhibiting an expression of a target gene that is Stathmin 1 in the one or more target cells via RNA interference, and the shRNAs target at least one of the 5′-UTR, the coding region, or the 3′-UTR of the Stathmin-1, or overlapping portions thereof in a therapeutic agent carrier complex to the subject in an amount sufficient to suppress the tumor cell growth;
wherein the one or more shRNAs comprise a bifunctional RNA molecule that activates a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of the target gene;
wherein the inhibition results in an apoptosis, an arrested proliferation, or a reduced invasiveness of the tumor cells.
20. The method of claim 19 , wherein the therapeutic agent carrier comprises a bilamellar invaginated vesicle (BIV).
21. The method of claim 19 , wherein the therapeutic agent carrier comprises one or more receptor targeting moieties that are small molecule bivalent beta-turn mimics.
22. The method of claim 19 , wherein administering is selected from the group consisting of subcutaneous, intravenous, intraperitoneal, intramuscular, and intravenous injection.
23. The method of claim 19 , wherein administering comprises intratumoral injection.
24. The method of claim 19 , wherein administering the composition comprises injecting with a DNA:lipoplex.
25. The method of claim 19 , wherein the bifunctional shRNA comprises a RNA sequence defined by at least one of DNA SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5.
26. The method of claim 19 , wherein at least one target site sequence is within a Stathmin 1 gene cDNA sequence.
27. The method of claim 19 , wherein at least one target site sequence is defined by SEQ ID NO: 1 or SEQ ID NO: 2.
28. The method of claim 19 , wherein the therapeutic agent carrier is a compacted DNA nanoparticle.
29. The method of claim 28 , wherein the DNA nanoparticle is compacted with one or more polycations.
30. The method of claim 29 , wherein the one or more polycations is a 10 kDA polyethylene glycol (PEG)-substituted cysteine-lysine 3-mer peptide (CK30PEG10k).
31. The method of claim 28 , wherein the compacted DNA nanoparticles are further encapsulated in a liposome.
32. The method of claim 19 , wherein the therapeutic agent carrier is a liposome.
33. The method of claim 32 , wherein the liposome is a reversibly masked liposome.